Dec 1, 2020
NCT04268498: Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)
The ADVANCE trial Dara-KRd KRd VRd NCT04268498: A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With...
1,067
Dec 10, 2010
NCT01080391: Comparing Carfilzomib, Lenalidomide & Dex (CRd) vs Lenalidomide and Dex (Rd) - ASPIRE
THE ASPIRE TRIAL Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in...
529
Dec 9, 2010
NCT01109004: Phase 3 - Stem Cell Transplant With Lenalidomide Maint. NDMM BMT CTN 0702 (STaMINA)
STaMINA Trial BMT CTN 0702 NCT01109004: Phase 3 - Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma...
177
Dec 14, 2008
NCT00689936: Phase 3 - Lenalidomide+low dose dex vs Melphalan, Prednisone, Thalidomide in NDMM FIRST
FIRST study IFM 07-01 CC-5013-MM020 Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan,...
440
Dec 14, 2007
NCT00511238: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
RRMM Relapsed and Refractory Multiple Myeloma NCT00511238: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma...
91